Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Cigna's Express Scripts launches cost-based drug pricing model

Published Nov 14, 2023 12:14PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
CI
+0.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

In a move to address the rising cost of prescription drugs in the United States, Cigna (NYSE:CI)'s pharmacy benefit manager (PBM) unit, Express Scripts, announced today the launch of its new cost-based pricing program named Express Scripts ClearNetwork. The program is set to transform how PBM clients, including employers and health plans, purchase medications by offering them at wholesale costs plus a maximum fee of 15%, starting from early 2024.

The ClearNetwork program will be available to over 65,000 participating pharmacies across the nation and applies to all drugs on a plan sponsor's formularies. This innovative pricing strategy reflects similar approaches taken by entities like Mark Cuban Cost Plus Drug Company, aiming to make drug costs more transparent and affordable.

Adam Kautzner, President of Express Scripts under Evernorth Health Services—a subsidiary of The Cigna Group—has emphasized the need for such a program in light of the regulatory scrutiny over PBMs' role in escalating US drug prices. Kautzner pointed out that high drug costs often stem from manufacturers' pricing strategies, which have been controversial and subject to debate.

The ClearNetwork determines drug acquisition costs using benchmarks such as Predictive Acquisition Cost, National Average Drug Acquisition Cost, and Wholesale Acquisition Cost. To these figures, pharmacy and administration costs are added, providing a clear picture of pricing.

In addition to the newly unveiled ClearNetworkSM, Express Scripts has been proactive in offering transparency initiatives like ClearCareRx™ and programs such as Copay Assurance Plan, SafeGuardRx®, Embarc Benefit Protection®, and Patient Assurance Program®. These programs have reportedly generated significant savings for consumers and clients in 2022, amounting to over $56 billion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Cigna's Express Scripts launches cost-based drug pricing model
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email